BTIG analyst Marie Thibault raised the firm’s price target on Delcath Systems to $20 from $19 and keeps a Buy rating on the shares. The analyst is updating the firm’s model following the company’s “regulatory win” yesterday as Delcath announced they received FDA approval for the HEPZATO KIT for the treatment of adults with unresectable hepatic-dominant metastatic uveal melanoma. The firm adds that it is taking a conservative approach and modeling initial revenue contribution beginning in early 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DCTH:
- Delcath Systems price target raised to $18 from $17 at H.C. Wainwright
- Unusually active option classes on open August 15th
- Delcath Systems (NASDAQ:DCTH) Skyrockets on FDA Approval for Hepzato Liver Therapy
- Delcath Systems price target raised to $18 from $14 at Canaccord
- Delcath Systems announces FDA approval of Hepzato KIT
